Long-acting inhaled bronchodilators, including anticholinergic Tiotropium ( Spiriva ), are recommended for the maintenance therapy of chronic obstructive pulmonary disease ( COPD ).
It has been shown in a number of studies that treatment with Tiotropium alleviates symptoms, improves exercise tolerance, health status, and reduces exacerbations in patients with moderate to very severe stage COPD.
The aim of this non-interventional study was to observe the early effects of the maintenance treatment with Tiotropium in patients with COPD of different severities, who had been previously treated on a regular basis, or as required, with at least one short-acting bronchodilator, in a real-life setting in Poland.
The effect of the treatment was assessed through the collection of COPD Assessment Test ( CAT ) data.
The MATHS clinical study was an observational, non-interventional, open-label, prospective, un-controlled, single-arm, postmarketing, surveillance, real-life study conducted with the involvement of 236 pulmonology clinics based in Poland.
The Tiotropium observational period was 3 months.
The health and COPD status was measured with the CAT questionnaire.
The primary efficacy endpoint was the mean change from the baseline in the total CAT score at the end of the 3-month observational period.
Patients treated with 18 mcg of Tiotropium once daily for 3 months showed a statistically significant result, with a clinically meaningful mean reduction ( improvement ) of 7.0 points in the total CAT score.
The improvement was slightly greater in patients with more severe COPD; the mean change in the total CAT score was 7.6 in the subgroup of patients with more severe COPD and 6.7 points in the subgroup of patients with moderate COPD.
In conclusion, results of this real-life study provide further support for the use of Tiotropium as a first-line maintenance treatment for patients with COPD of different severities in Poland. ( Xagena )
Jahnz-Różyk K, Szepiel P, Int J Chron Obstruct Pulmon Dis 2015; 10: 613–623